Keywords: پانیتومومب; EGFR; TKIs; Monoclonal antibodies; Toxicity; Gastrointestinal cancer; Panitumumab; Cetuximab;
مقالات ISI پانیتومومب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پانیتومومب; Metastatic colorectal cancer; Primary tumour location; Sidedness; Prognostic biomarker; Predictive biomarker; Cetuximab; Panitumumab; Bevacizumab; Anti-EGFR; Anti-VEGF;
Keywords: پانیتومومب; Bevacizumab; Cetuximab; Chemotherapy; Colorectal cancer; Panitumumab;
Keywords: پانیتومومب; Cetuximab; HER2; MET; Panitumumab; Targeted therapy;
Keywords: پانیتومومب; Common Toxicity Criteria for Adverse Events; epidermal growth factor receptor inhibitors; panitumumab; papulopustular rash; skin toxicity; CTCAE; Common Toxicity Criteria for Adverse Events; EGFR; epidermal growth factor receptor; PMCC; Princess Margaret
Keywords: پانیتومومب; Adverse events; Cetuximab; Elderly; Panitumumab; Performance status;
Keywords: پانیتومومب; Carcinoembryonic antigen; Metastatic colorectal cancer; Monotherapy; Panitumumab; Response;
Keywords: پانیتومومب; Advanced colorectal cancer; Metastatic colorectal cancer; Monoclonal antibody; Bevacizumab; Cetuximab; Panitumumab; Targeted therapy; Health economics; Cost-effectiveness analysis; Cost-utility analysis;
Keywords: پانیتومومب; Biomarker; Cetuximab; Colorectal cancer; Companion diagnostic; Epidermal growth factor receptor; Genomics; KRAS testing; Panitumumab; Personalised medicine; Targeted therapy;
Keywords: پانیتومومب; Cetuximab; Elderly; Metastatic colorectal cancer; Panitumumab; Review
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy
Keywords: پانیتومومب; Anal cancer; Immunotherapy; Nivolumab; Anti-EGFR; Cetuximab; Pembrolizumab; Panitumumab;
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO
Keywords: پانیتومومب; Oesophagogastric adenocarcinoma; Perioperative; Panitumumab; EGFR; HER2; MET;
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
Keywords: پانیتومومب; Bilary cancer; Chemotherapy; Panitumumab; Genetic profiling; KRAS; EGFR;
Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status
Keywords: پانیتومومب; Chemotherapy; Overall survival; Panitumumab; Prognosis; Progression-free survival;
Case reportCurative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: A case report
Keywords: پانیتومومب; CRC; colorectal cancer; Pmab; Panitumumab; EGFR; Epidermal growth factor receptor; CT; Computed tomography; PFS; Progression-free survival; OS; Overall survival; Neoadjuvant chemotherapy; Sigmoid colon cancer; Panitumumab; Case report;
Mini-reviewCo-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer
Keywords: پانیتومومب; Colorectal cancer; Epidermal growth factor receptor; Autophagy; Endocytosis; Panitumumab; Cetuximab;
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
Keywords: پانیتومومب; Panitumumab; FOLFOX; FOLFIRI; Metastatic colorectal cancer; First-line; Liver-limited disease; Resection;
HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy
Keywords: پانیتومومب; Cetuximab; EGFR; Gastrointestinal; Panitumumab; Targeted therapy;
Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839
Keywords: پانیتومومب; NSCLC; Chemoradiotherapy; Preoperative; Multimodality; EGFR antibody; Panitumumab;
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
Keywords: پانیتومومب; Squamous cell carcinoma; Head and neck cancer; Recurrent; Metastatic; Panitumumab; Paclitaxel;
Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed
Keywords: پانیتومومب; Epidermal growth factor receptor; Monoclonal antibody; Panitumumab; Penile cancer; Penilae squamous cell carcinoma
ReviewRAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer
Keywords: پانیتومومب; Cetuximab; KRAS; mCRC; NRAS; Panitumumab;
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer
Keywords: پانیتومومب; Anti-EGFR therapy; Colorectal cancer; Gastrointestinal cancer; Panitumumab;
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck
Keywords: پانیتومومب; Head and neck cancer; Squamous cell carcinoma; Panitumumab; Anti-EGFR therapy; Docetaxel/cisplatin; Human papillomavirus (limit 1–10)
A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer
Keywords: پانیتومومب; Bevacizumab; Cetuximab; Panitumumab; Meta-analysis; Survival; Progression-free survival;
Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy
Keywords: پانیتومومب; cetuximab; colorectal cancer; cost-effectiveness; cost-minimization; panitumumab; subsequent-line;
Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
Keywords: پانیتومومب; Chemotherapy; EGFR inhibitor; Metastatic breast cancer; Panitumumab; Triple-negative breast cancer;
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
Keywords: پانیتومومب; Metastatic colorectal cancer; RAS mutation; Biomarker; EGFR; Panitumumab; Cetuximab;
MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using 64Cu-NOTA-panitumumab F(ab')2 fragments
Keywords: پانیتومومب; Epidermal growth factor receptor (EGFR); Positron emission tomography (PET); Pancreatic cancer; Panitumumab; Tumor models; Copper-64;
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Keywords: پانیتومومب; BRAF mutation; Colorectal cancer; Meta-analysis; Cetuximab; Panitumumab;
Análisis de costo-efectividad de panitumumab + FOLFOX en CCRm RAS-WT
Keywords: پانیتومومب; Panitumumab; Bevacizumab; Cáncer colorrectal metastásico; RAS naturalPanitumumab; Bevacizumab; Metastatic colorectal cancer; Wild-type RAS
CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status
Keywords: پانیتومومب; Epidermal growth factor receptor; KRAS; Non-small cell lung cancer; Panitumumab; Pemetrexed/cisplatin;
Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials
Keywords: پانیتومومب; Panitumumab; mCRC; RAS prevalence; KRAS; NRAS; BRAF;
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours
Keywords: پانیتومومب; Panitumumab; Colorectal cancer; Monotherapy; First-line; Elderly patients; Frailty;
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
Keywords: پانیتومومب; Cetuximab; Panitumumab; Bevacizumab; Colorectal cancer; Overall survival; Randomized clinical trials
Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer
Keywords: پانیتومومب; FOLFOX4; Colorectal neoplasms; Panitumumab; Progression-free survival; RAS genes;
Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials
Keywords: پانیتومومب; Anti-egfr monoclonal antibodies; Cetuximab; Panitumumab; Colorectal cancer; Adverse events; Diarrhoea; Mucositis; Pharmacovigilance; Systematic review; Meta-analysis
Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells
Keywords: پانیتومومب; HNSCC; EGFR; Knockdown; Cetuximab; Panitumumab;
Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis
Keywords: پانیتومومب; Anti-EGFR monoclonal antibody; Cetuximab; Febrile neutropenia; Infection; Meta-analysis; Panitumumab; Systematic review;
Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
Keywords: پانیتومومب; Cost-effectiveness; Panitumumab; Bevacizumab; Colorectal cancer;
Acquired resistance to EGFR-targeted therapies in colorectal cancer
Keywords: پانیتومومب; Anti-EGFR therapy; Cetuximab; Panitumumab; Colorectal cancer; Acquired resistance; RAS; MET
MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies
Keywords: پانیتومومب; Cetuximab; Let-7c; miR-99a; miR-125b; Panitumumab;
Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: Prognostic value of MAGE-A subgroups for treatment success
Keywords: پانیتومومب; MAGE-A; Tumour antigen; Cetuximab; Panitumumab; EGFR;
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
Keywords: پانیتومومب; Adenocarcinoma; Biomarker; Chemotherapy; EGFR; Gastric; Oesophageal; Oesophagogastric; Palliative; Panitumumab; Peri-operative;
Keywords: پانیتومومب; cetuximab; colorectal cancer; cost-effectiveness; cost-utility; decision analytic modeling; Erbitux; irinotecan; panitumumab; Vectibix
Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab
Keywords: پانیتومومب; Cetuximab; Magnetic resonance imaging; Metastatic colorectal cancer; Panitumumab; Predictor clinical outcome
A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Keywords: پانیتومومب; Panitumumab; Paclitaxel/carboplatin; Non–small-cell lung cancer; KRAS; Epidermal growth factor receptor
Ãtude observationnelle sur les conditions d'accès à l'analyse de la mutation du gène KRAS chez les patients atteints de cancer colorectal métastatique recevant un traitement par panitumumab
Keywords: پانیتومومب; anticorps anti-EGFR; panitumumab; cancer colorectal; KRAS; génotypage; anti-EGFR antibodies; panitumumab; colorectal cancer; KRAS; genotyping;
The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis
Keywords: پانیتومومب; cancer; cetuximab; EGFR inhibitor; erlotinib; lapatinib; nail toxicity; panitumumab; paronychiaAE, adverse event; CI, confidence interval; CTCAE, Common Terminology Criteria for Adverse Events (CTCAE); EGFR, epidermal growth factor receptor; EGFRIs, epide
Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma
Keywords: پانیتومومب; Cetuximab; Chemotherapy; Epidermal growth factor receptor; Metastatic colorectal cancer; Panitumumab